Nyxoah (NASDAQ:NYXH – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $2.02 million for the quarter.
Nyxoah Stock Performance
NASDAQ NYXH opened at $10.21 on Thursday. The company has a fifty day simple moving average of $10.05 and a 200 day simple moving average of $9.11. Nyxoah has a 12-month low of $6.76 and a 12-month high of $20.00. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The company has a market cap of $347.75 million, a P/E ratio of -5.46 and a beta of 1.41.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Nyxoah in a research report on Friday, December 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.00.
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
See Also
- Five stocks we like better than Nyxoah
- What is a Dividend King?
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- What is Short Interest? How to Use It
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- The 3 Best Retail Stocks to Shop for in August
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
